Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Snap Inc (SNAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Snap Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Snap Inc trades at $4.67 (market cap $7.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.1× Snap Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SNAP | |
|---|---|---|
Market Cap | $39.89B | $7.87B |
Sector | Health | Media |
52-Week High | $491.22 | $10.35 |
52-Week Low | $278.09 | $3.93 |
Enterprise Value | $38.15B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Snap Inc. (SNAP) trades at $4.68, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported revenue of $5.93 billion in 2025, with a net loss narrowing to -$460 million, showing improved profitability trends. Recent news highlights the launch of SPECS AR glasses priced at $2,195, which has drawn investor skepticism over pricing and demand.
The outlook remains cautious; while Snap has beaten EPS estimates in recent quarters and holds a consensus price target of $6.92, high debt levels and persistent net losses pose risks. Investor sentiment is mixed amid competitive pressures and regulatory scrutiny, requiring careful evaluation of growth initiatives against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
